Author: Bae, Joon-Yong; Lee, Gee Eun; Park, Heedo; Cho, Juyoung; Kim, Jeonghun; Lee, Jungmin; Kim, Kisoon; Kim, Jin Il; Park, Man-Seong
Title: Antiviral Efficacy of Pralatrexate against SARS-CoV-2 Cord-id: 944ckuen Document date: 2021_5_1
ID: 944ckuen
Snippet: Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral
Document: Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner. In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells. Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy.
Search related documents:
Co phrase search for related documents- addition time and madin darby: 1, 2
- addition time assay and lung epithelial cell: 1
Co phrase search for related documents, hyperlinks ordered by date